Date:
October 19, 2020
Issue #:
1609
Summary:
The FDA has approved insulin lispro-aabc (Lyumjev –
Lilly), a faster-acting formulation of insulin lispro
(Humalog), for treatment of type 1 and type 2 diabetes
in adults. Fiasp, a faster-acting formulation of insulin
aspart (Novolog), was approved in 2017.
Lilly), a faster-acting formulation of insulin lispro
(Humalog), for treatment of type 1 and type 2 diabetes
in adults. Fiasp, a faster-acting formulation of insulin
aspart (Novolog), was approved in 2017.